Takeaway

• The addition of atezolizumab immunotherapy (vs no atezolizumab) to chemotherapy fails to improve pathologic complete response (pCR) in triple-negative breast cancer (TNBC), both early high-risk and locally advanced, according to the NeoTRIP trial.
• The rate of serious adverse events is higher in the atezolizumab group.

Why this matters

• pCR...